ARHGEF2 was one of multiple genes that displayed an altered response after treatment with Imatinib in gastrointestinal stromal tumors [17] suggesting that targeting ARHGEF2 expression could be an attractive therapeutic treatment for susceptible cancer types. The gene discussed is ARHGEF2; the disease is cancer.